Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
81 hedge funds and large institutions have $252M invested in Avadel Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 18 closing their positions.
114% more call options, than puts
Call options by funds: $5.48M | Put options by funds: $2.56M
1.14% more ownership
Funds ownership: 59.6% → 60.74% (+1.1%)
4% less funds holding
Funds holding: 84 → 81 (-3)
11% less capital invested
Capital invested by funds: $282M → $252M (-$30.1M)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.99M |
| 2 |
Janus Henderson Group
London,
|
+$2.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$2.78M |
| 4 |
GJL
Gendell Jeffrey L
|
+$2.69M |
| 5 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$7.69M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.56M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.54M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.29M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.01M |
AVDL Hedge Fund Activity: Q1 2022 in Review
81 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2022, worth a combined $252M — down 11% from $282M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AVDL and 16 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 20 added.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $3.99M. The largest seller was Frazier Management, exiting entirely with an estimated $7.69M sold.
- 81 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2022, down from 84 in Q4 2021.
- Funds reported $252M of Avadel Pharmaceuticals stock for Q1 2022, down 11% quarter-over-quarter.
- 16 funds opened new Avadel Pharmaceuticals positions in Q1 2022 and 18 closed out, a net change of -2 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2022 was Acuta Capital Partners, an estimated $3.99M added.
- The largest Avadel Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $7.69M sold.
Based on aggregated 13F filings for Q1 2022.